Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported open-market sales of a total of 80,000 shares of common stock on May 8, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026.
The sales were broken into four trades at weighted average prices between about $72.57 and $75.35 per share. Footnotes state that each reported price is a weighted average, with individual trades occurring in ranges from $72.03 up to $75.71 per share.
Spyre Therapeutics reported first quarter 2026 results showing continued investment in its pipeline and a larger net loss. Net loss was $69.0 million compared with $44.8 million a year earlier, driven by higher R&D and G&A spending and a swing to other expense from prior-year income.
R&D rose to $60.4 million as manufacturing, clinical trial activity, and headcount increased. G&A reached $15.2 million. The company recorded a $30.0 million gain tied to FDA approval milestones from a prior asset sale, partly offset by higher contingent value right liability, which contributed to $23.4 million in other expense. Spyre ended March 31, 2026 with $741.5 million in cash, cash equivalents, and marketable securities, and reported $1,176.8 million of pro forma cash including April 2026 equity offering proceeds, which it expects will fund operations into the second half of 2029.
Spyre Therapeutics, Inc. reported a net loss of $69.0 million for the quarter ended March 31, 2026, wider than $44.8 million a year earlier, driven mainly by higher research and development spending of $60.4 million and increased general and administrative expenses of $15.2 million.
The company recorded a $30.0 million gain from a milestone on the prior sale of pegzilarginase rights to Immedica, while its contingent value right (CVR) liability rose to $56.9 million. Cash, cash equivalents and marketable securities totaled $741.5 million as of March 31, 2026, before an additional $435.3 million in net proceeds from an April 2026 equity offering.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a planned option exercise and share sale on Common Stock. On May 1, 2026, he sold 12,500 shares of Common Stock in an open-market transaction at $71.37 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
The same day, he exercised stock options to acquire 12,500 shares of Common Stock at an exercise price of $14.50 per share. Following these transactions, he directly holds 110,494 shares of Common Stock, which include 67,476 restricted stock units scheduled to vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. He also retains stock options representing a right to purchase 404,857 shares of Common Stock, vesting over several years.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported coordinated stock trades involving both option exercise and share sales. On May 1, 2026, Sloan exercised stock options to acquire 78,333 shares of common stock at an exercise price of $27.46 per share.
That same day, Sloan executed multiple open-market sales totaling 78,333 shares of common stock at weighted average prices reported around the low- to mid-$70s per share, with detailed price ranges from $69.21 to $74.96 disclosed in the footnotes. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025.
The option exercised covers a grant originally for 400,000 shares of common stock, with 321,667 option shares remaining outstanding after this exercise and an expiration date of October 1, 2034, subject to continued vesting based on employment.
Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock in multiple open-market transactions on May 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan.
The sales occurred at weighted-average prices, with transaction price ranges disclosed between $69.25 and $74.96 per share across several blocks. After these transactions, the filing shows that Turtle continues to hold Spyre common stock directly.
SYRE reports transactions in Common Stock under Rule 144. The excerpt lists an exercise of stock options resulting in 78,333 shares on 05/01/2026, and prior 10b5-1 sales of 7,958 shares on 04/01/2026 for $397,900. Broker: Morgan Stanley Smith Barney LLC.
Company reporting a Form 144 filing that lists 27,500 shares of Common Stock proposed for sale. The filing ties the sale to an exercise of stock options on 05/01/2026 with cash indicated as the method. The filing also discloses recent 10b5-1 sales: 7,500 shares sold on 04/01/2026 for $370,066.25 and 2,500 shares sold on 03/03/2026 for $101,620.50.
SPYRE THERAPEUTICS, INC. Schedule 13G: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report beneficial ownership of 4,319,496 shares of Common Stock, representing 5.0% of the class. The filing states the outstanding share count as 85,664,811 shares as reported in a prospectus supplement filed April 16, 2026. Perceptive Life Sciences Master Fund directly holds the shares; Perceptive Advisors and Mr. Edelman disclose shared voting and dispositive power as investment manager and managing member, respectively.